Overall, I won't disagree, cu6's trials are generally overlooked when you read up about upcoming RLT. Surprisingly, actinium gets a nod, due to its more potent alpha particles, but with a shorter distance of effect.
maybe it's because cu6 is arguably less than halfway through their first theranostics trial for mcrpc. I find it hard believe we won't be on anyone's radar if the results continues the current trends after even their double dosing schedule is completed.
Research/Valuation, page-63
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.46 |
Change
0.310(4.34%) |
Mkt cap ! $2.356B | |||
| Open | High | Low | Value | Volume |
| $7.22 | $7.58 | $7.17 | $6.459M | 870.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 1651 | $7.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.47 | 3949 | 6 |
View Market Depth
| Last trade - 15.24pm 06/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |